Intrinsic and extrinsic factors controlling benign prostatic growth

Prostate

Volumn 31, Issue 2, 1997, Pages 131-138

  Lee, Chung ^a   Kozlowski, James M ^a   Grayhack, John T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

environmental factors; genetic factors; non testicular factors; stromal epithelial interaction; testicular factors

Indexed keywords

ANDROGEN; ESTROGEN; KERATINOCYTE GROWTH FACTOR; NEUROTRANSMITTER; TRANSFORMING GROWTH FACTOR BETA;

DIET; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GENETIC PREDISPOSITION; HEREDITY; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; STROMA CELL; TESTIS;

EID: 0030907796     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970501)31:2<131::AID-PROS9>3.0.CO;2-Q     Document Type: Review

References (83)

1. White JW: The present position of surgery of the hypertrophied prostate. Ann Surg 18:152, 1893.
2. Rand HW: A contribution to the surgery of the hypertrophied prostate. Ann Surg 22:217-225, 1895.
3. Moore RA: Benign hypertrophy and carcinoma of the prostate: Occurrence and experimental production in animals. Surgery 16:152-167, 1944.
4. Wu JP, Gu FL: The prostate 41-65 years post-castration: An analysis of 26 eunuchs. Chin Med J [Engl] 100:271-272, 1987.
5. Cunha GR: The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 175:87-96, 1973.
6. Cunha GR: Tissue interactions between epithelium and mesenchyme of urogenital and integumental origin. Anat Rec 172:529-541, 1972.
7. Chung LWK, Cunha GR: Stromal-epithelial interactions. II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 4:503-511, 1983.
8. Chung LWK, Matsuura J, Runner MR: Tissue interactions and prostatic growth: I. Induction of adult mouse prostatic hyperplasia by fetal urogenital sinus implants. Biol Reprod 31:155-163, 1984.
9. Lee C, Sensibar JA, Dudek SM, Hiipakka RA, Liao S: Prostatic ductal system in rats: Regional variation in morphological and functional activities. Biol Reprod 43:1079-1086, 1990.
10. Sensibar JA, Griswold MD, Sylvester SR, Buttyan R, Bardin CW, Cheng CY, Dudek S, Lee C: Prostatic ductal system in rats: Regional variation in localization of an androgen-repressed gene product, sulfate glycoprotein-2. Endocrinology 128:2091-2102, 1991.
11. Nemeth JA, Lee C: The prostatic ductal system in rats: Regional variation in stromal organization. Prostate 28:124-128, 1996.
12. Yan G, Fukabori Y, Nikolaropolous S, Wang F, McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 6:2123-2128, 1992.
13. Nemeth JA, Sensibar JA, Lee C: Changes in TGF-β localization in the rat prostatic ductal system during castration-induced regression. Presented at the 77th Annual Meeting for the Endocrine Society, Washington, D.C., June 14-17, 1995 (abstract P1-361).
14. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13:4513-4522, 1993.
15. Kim IY, Ahn HJ, Zelner DJ, Park L, Sensibar JA, Lee C: Expression and localization of transforming growth factor-β receptors type I and II in the rat ventral prostate during regression. Mol Endocrinol 10:107-115, 1996.
16. Peehl DM, Stamey TA, Rubin JS: Fibroblast growth factors can replace epidermal growth factor for clonal proliferation of human prostatic epithelial cells. J Urol 145:475, 1991.
17. Sugumura Y, Cunha GR, Haywood S, Hayashi N, Arima K, Kawamura J: Kartinocyte growth factor (KGK) is a mediator of testosterone induced prostatic development. J Urol 151:381, 1994.
18. Alarid ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, Cuhna GR: Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci USA 91:1074-1078, 1994.
19. Culig Z, Hobixch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478, 1994.
20. Guo L, Degenstein L, Fuchs E: Keratinocyte growth factor is required for hair development but not for wound healing. Genes Dev 10:165-175, 1996.
21. Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C: Interaction of epidermal growth factor and transforming growth factor β in human prostatic epithelial cells in culture. Prostate 21:133-143, 1992.
22. Ilio KY, Sensibar JA, Lee C: Effect of TGF-β1, TGF-α, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl 16:482-490, 1995.
23. Mao P, Angrist A: The fine structure of the basal cell of human prostate. Lab Invest 15:1768-1782, 1966.
24. Aumuller G: Morphologic and endocrine aspects of prostatic function. Prostate 4:195-214, 1983.
25. Di Sant' Agnese PA, de Mesy Jensen KL, Churukian CJ, Agarwal MM: Human prostatic endocrine-paracrice (APUD) cells. Arch Pathol Lab Med 109:607-612, 1985.
26. Srigley JR, Dardick I, Warren R, Hartwick J, Klotz L: Basal epithelial cells of human prostate gland are not myoepithelial cells. Am J Pathol 136:957-966, 1990.
27. Sherwood ER, Fong CJ, Lee C, Kozlowski JM: Basic fibroblastic growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 130:2955-2963, 1992.
28. Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. In Lepor H, Lawson RK (eds): "Prostate Diseases." Philadelphia: W.B. Saunders Co., 1993, pp 96-107.
29. Bruchovsky N, Lesser B, van Doom E, Craven S: Hormonal effect on cell proliferation in rat prostate. Vitam Horm 33:61-102, 1975.
30. Kyprianou N, Isaacs JT: Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept. Prostate 11:41-50, 1987.
31. Lee C: Physiology of castration-induced regression in rat prostate. Prog Clin Biol Res 75:145-159, 1981.
32. Isaacs JT: Antagonistic effect of androgens on prostatic cell death. Prostate 5:545-557, 1984.
33. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562, 1988.
34. McKeehan WL, Adams PS, Rosser MP: Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors, and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 44:1998-2010, 1984.
35. Rubens R, Dhont M, Vermeulen A: Further studies on Leydig cell function in old age. J Clin Endocrinol Metab 39:40-45, 1974.
36. Riad-Fahmy D, Read GF, Walker RF, Griffiths K: Steroids in saliva for assessing endocrine function. Endocr Rev 3:367-395, 1982.
37. Krieg M, Bartsch W, Thomsen M, Voigt KD: Androgens and estrogens: Their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem 19:155-161, 1983.
38. Collins AT, Zhiming B, Gilmore K, Neal DE: Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: Oestrogen regulation of the androgen receptor. J Endocrinol 143:269-277, 1994.
39. DeKlerk DP, Coffey DS, Ewing LL, McDermott IR, Reiner WG, Robinson CH, Scott WW, Strandberg JD, Talaly D, Walsh PC, Wheaton LG, Zirkin BR: Comparison on spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 64:842-849, 1979.
40. Grayhack JT: Effect of testosterone-estradil administration on citric acid and fructose content of the rat prostate. Endocrinology 77:1068-1074, 1965.
41. Lee C, Prins GS, Henneberry MO, Grayhack JT: Effect of estradiol on the rat prostate in the presence and absence of testosterone and pituitary. J Androl 2:293-299, 1981.
42. Nakhla AM, Khan MS, Romas NP, Rosner W: Estradiol causes the rapid accumulation of cAMP in human prostate. Proc Natl Acad Sci USA 91:5402-5405, 1994.
43. Farnsworth WE: Role of estrogen and SHBG in prostate physiology. Prostate 28:17-23, 1996.
44. Ikonen T, Palvimo JJ, Kallio PJ, Reinkainen P, Janne OA: Stimulation of androgen-regulated transcription by modulators of protein phosphorylation. Endocrinology 135:1359-1366, 1994.
45. McNeal JE: Developmental and comparative anatomy of the prostate. In Grayhack JT, Wilson JD, Scherbenske MJ (eds): "Benign Prostatic Hyperplasia," DHEW Publication no. (NIH) 76-1113. Bethesda: National Institutes of Health, 1975, pp 1-9.
46. Grayhack JT: Changes with aging in human seminal vesicle fluid fructose concentration and seminal vesicle weight. J Urol 86:142-148, 1961.
47. Grayhack JT, Lee C, Brand W: The effect of testicular irradiation on established BPH in the dog: Evidence of a non-steroidal testicular factor for BPH maintenance. J Urol 134:1276-1281, 1985.
48. Dalton DP, Lee C, Huprikar S, Chmiel JS, Grayhack JT: Non-androgenic role of testis in enhancing ventral prostate growth in rats. Prostate 16:225-233, 1990.
49. Darras FS, Lee C, Huprikar S, Rademaker AW, Grayhack JT: Evidence for a non-androgenic role of testis and epididymis in androgen-supported growth of the rat ventral prostate. J Urol 148:432-140, 1992.
50. Juniewicz PE, Berry SJ, Coffey DS, Strandberg JD, Ewing LL: Requirement of testis in establishing sensitivity of canine prostate to develop benign prostatic hyperplasia. J Urol 152:996-1001, 1994.
51. Cooke PS, Meisami E: Early hypothyroidism in rats causes increased adult testis and reproductive organ size but does not change testosterone levels. Endocrinology 129:237-243, 1991.
52. Larriva-Sahd J, Orozco H, Hernandez-Pando R, Oliart RM, Musto NA, Larrea F: Immunohistochemical demonstration of androgen-binding protein in the rat prostatic gland. Biol Reprod 45:417-123, 1991.
53. Rosner W: Plasma steroid-binding proteins. Endocrinol Metab Clin North Am 20:697-720, 1991.
54. Sutkowski DM, Kasjanski RE, Sensibar JA, Ney KG, Lim DJ, Kozlowski JM, Lee C, Grayhack JT: Effect of spermatocele fluid on growth of human prostatic cells in culture. J Androl 14:233-239, 1993.
55. Grayhack JT, Bunce PL, Kearns JW, Scott WW: Influence of the pituitary on prostatic response to androgen in the rat. Bull Johns Hopkins Hosp 96:154-163, 1955.
56. Grayhack JT: Pituitary factors influencing growth of the prostate. Natl Cancer Inst Monogr 12:198-199, 1963.
57. 65Zn by the rat dorsalateral prostate. J Endocrinol 32:205-219, 1965.
58. Farnsworth WE: Prolactin effect on the permeability of human benign hyperplastic prostate to testosterone. Prostate 12:221-229, 1988.
59. Lee C, Grayhack JT: Prolactin and prostate in animal models. In Nagasawa H (ed): "Prolactin and Lesions in Breast, Uterus and Prostate." Boca Raton, FL: CRC Press, 1989, pp 177-186.
60. Fekete M, Redding TW, Comaru-Schally AM, Powtes JE, Connelly RW, Srkalovic G, Serially AV: Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 14:191-208, 1989.
61. Harper ME, Pike A, Peeling WB, Griffiths K: Steroids of adrenal origin metabolised by human prostatic tissue both in vivo and in vitro. J Endocrinol 60:117-125, 1974.
62. Schweikert HU, Totzauer P, Rohr HP, Bartsch G: Correlated biochemical and stereological studies on testosterone metabolism in the stromal and epithelial compartment of human benign prostatic hyperplasia. J Urol 134:403-407, 1985.
63. Ip NY, Ibanez CF, Nye SH, McClain J, Jones PF, Gies DR, Belluscio L, LeBeau MM, Espinosa R, Squinto SP, Persson H, Yancopoulos GD: Mammalian neurotrophin-4 structure, chromosomal localization, tissue distribution, and receptor specificity. Proc Natl Acad Sci USA 89:3060-3064, 1992.
64. Caine M, Raz S, Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostate capsule, and bladder neck. Br J Urol 47:193-209, 1975.
65. Shapiro E, Hartanto V, Lepor H: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21:297-303, 1992.
66. Djakiew D: Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl 13:476-487, 1992.
67. Graham C, Lynch JH, Djakiew D: Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147:1444-1447, 1992.
68. Lepor H: The role of alpha blockade in the therapy of benign prostatic hyperplasia. In Lepor H, Lawson RK (eds): "Prostate Diseases." Philadelphia: W.B. Saunders Co., 1993, pp 170-181.
69. h: A GTP-binding protein with transglulaminase activity and receptor signaling function. Science 264:1593-1596, 1994.
70. Robinette CL: Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 12: 271-286, 1988.
71. Kohnen PW, Drach GW: Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol 121: 755-760, 1979.
72. Wright ET, Chmiel JS, Grayhack JT, Schaeffer AJ: Prostatic fluid inflammation in prostatitis. J Urol 152:2300-2303, 1994.
73. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner G: Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 66:96-107, 1992.
74. Steiner G, Gesse A, Kramer G, Schollhammer A, Forster O, Marberger M: Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 151:480-484, 1994.
75. Barbul A, Shawe T, Rotter SM, Efron ZE, Wasserbrug LH, Badawy SB: Wound healing in nude mice: A study on the regulatory role of lymphocytes in fibroplasia. Surgery 105:764-769, 1989.
76. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M: T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 91:2890-2894, 1994.
77. Ekman P: BPH epidemiology and risk factors. Prostate [Suppl] 2:23-31, 1989.
78. Breslow NE, Cahn CW, Dhom G, Drury RAB, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius M: Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 20:680-688, 1977.
79. Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton M: "Diet and Cancer: Prostate and Breast." Oxford: ISIS Medical Media, in press (1997).
80. Liao S, Hiipakka RA: Selective inhibition of steroid 5α-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 214:833-838, 1995.
81. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA: Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 96: 239-243, 1995.
82. Dolle P, Izpisua-Belmonte JC, Brown JM, Tickle C, Duboule D: Hox-4 genes and the morphogenesis of mammalian genitalia. Genes Dev 5:1767-1772, 1991.
83. Imperato-McGinley J, Guerro L, Gautier T, Peterson RE: Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 186:1213-1215, 1974.